Xcout Intel
CytoReason
CytoReason provides a computational disease modeling platform designed for pharmaceutical R&D. The company's technology uses human data to help scientists and executives map disease mechanisms, prioritize drug portfolios, and predict treatment performance.
Subscribe to see CytoReason’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CytoReason at a glance
CytoReason is a biotech company headquartered in Israel, founded in 2016. It has raised at least $100M across the 2 funding rounds on record. Its most recent funding round raised $80M in July 2024. Xcout tracks 1 named person at CytoReason, including Mike Vincent (SVP Immunology & Inflammation). Xcout recorded 1 job posting from CytoReason in the last 90 days.
CytoReason leadership
- Mike VincentSVP Immunology & Inflammation
CytoReason funding rounds
At least $100M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $80M | 4 named | |
| — | $20M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at CytoReason
Xcout recorded 1 job posting from CytoReason in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see CytoReason's hiring signals →
Investors
CytoReason competitors
A few of CytoReason's closest competitors — see the full list of competitors and alternatives →
Cellarity is a U.S. biotechnology company that uses single-cell biology, computational modeling, and machine learning to discover medicines based on cellular behaviors and disease mechanisms. It serves pharmaceutical and biotechnology development needs, advancing its own therapeutic programs and potentially partnering with other drug developers.
Axiom Bio is a biotechnology company that develops AI-driven predictive models and translational intelligence tools to assess drug toxicity and minimize clinical trial failures in drug discovery.
Sightera Biosciences is an Antwerp-based biotechnology startup leveraging clinically correlated patient data and an artificial intelligence platform to advance drug discovery and design.
Auransa is a clinical-stage, AI-native biopharmaceutical company headquartered in Palo Alto, California. It utilizes a proprietary artificial intelligence platform to mine massive human disease datasets for discovering novel therapeutics.
Cypre Inc. is a biotechnology company headquartered in San Francisco, California, that develops 3D tumor models and oncology platforms for drug discovery.
Nosis Biosciences develops receptor-targeted RNA medicines utilizing its proprietary AI-powered platform, Connexa, which combines physics-aware deep learning, single cell biology, and high-throughput chemistry. The company's platform designs gene-silencing therapeutics intended to treat chronic conditions across various cell types and organ systems, including the heart, lungs, kidneys, and brain.
Get CytoReason's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about CytoReason? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CytoReason in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access